Cited by 51Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Diagnosis and Management of Posterior Cortical Atrophy

Open access
Yong, Keir X. X., Graff-Radford, Jonathan, Ahmed, Samrah, Chapleau, Marianne, Ossenkoppele, Rik, Putcha, Deepti, Rabinovici, Gil D., Suarez-Gonzalez, Aida +3 more·2023·Current Treatment Options in Neurology

Abstract

Purpose of review: The study aims to provide a summary of recent developments for diagnosing and managing posterior cortical atrophy (PCA). We present current efforts to improve PCA characterisation and recommendations regarding use of clinical, neuropsychological and biomarker methods in PCA diagnosis and management and highlight current knowledge gaps. Recent findings: Recent multi-centre consensus recommendations provide PCA criteria with implications for different management strategies (e.g. targeting clinical features and/or disease). Studies emphasise the preponderance of primary or co-existing Alzheimer’s disease (AD) pathology underpinning PCA. Evidence of approaches to manage PCA symptoms is largely derived from small studies. Summary: PCA diagnosis is frequently delayed, and people are likely to receive misdiagnoses of ocular or psychological conditions. Current treatment of PCA is symptomatic — pharmacological and non-pharmacological — and the use of most treatment options is based on small studies or expert opinion. Recommendations for non-pharmacological approaches include interdisciplinary management tailored to the PCA clinical profile — visual-spatial — rather than memory-led, predominantly young onset — and psychosocial implications. Whilst emerging disease-modifying treatments have not been tested in PCA, an accurate and timely diagnosis of PCA and determining underlying pathology is of increasing importance in the advent of disease-modifying therapies for AD and other albeit rare causes of PCA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11940-022-00745-0

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A retrospective study suggested that ChEIs may help stabilize cognitive and functional decline in logopenic variant primary progressive aphasia (lvPPA), similar to their effects in amnestic Alzheimer's disease.

    “A retrospective study suggested that ChEIs may help stabilize cognitive and functional decline in lvPPA, similar to their effects in amnestic AD.51”

    From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [51]

    The Pharmacological management section recommends acetylcholinesterase inhibitors for posterior cortical atrophy, while Memory and language notes an overlap between posterior cortical atrophy and lvPPA. Neither section reports a retrospective lvPPA study or says that these drugs stabilize cognitive and functional decline in lvPPA compared with amnestic AD; searches for those terms found no such passage in our copy. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yong, K. X. X., Graff-Radford, J., Ahmed, S., Chapleau, M., Ossenkoppele, R., Putcha, D., Rabinovici, G. D., Suarez-Gonzalez, A., Schott, J. M., Crutch, S., & Harding, E.
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • University of Oxford (GB)
  • University of California, San Francisco (US)
  • Lund University (SE)
  • Harvard University (US)
Corresponding author
Yong, Keir X. X.
Venue
Current Treatment Options in Neurology
Published
2023-02
Volume
25
Issue
2
Pages
23-43
ISSN
  • 1092-8480 (ISSN-L)
  • 1534-3138
OpenAlex
W4319596989
Cited by
51
References
97
Citations by year
2026: 10 · 2025: 17 · 2024: 20 · 2023: 4
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • Current Treatment Options in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • CentAUR (University of Reading) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Alzheimer's Society (AS-JF-18-003)
  • NIH Clinical Center (R01EY027964, AG050603, P30-AG062422, R35 AG072362)
  • Wellcome Trust (204841/Z/16/Z)
  • Alzheimer's Association (ZEN-21-848216)
  • ESRC-NIHR (ES/S010467/1, ES/L001810/1)
  • NIHR (cov-lt2-0014)
  • Economic and Social Research Council (ES/W006014/1)
  • Alzheimer Society (AS-PG-14-022)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
posterior cortical atrophy, diagnosis, management, Alzheimer's disease pathology, biomarkers, neuropsychological assessment, clinical criteria, misdiagnosis, non-pharmacological treatment, disease-modifying therapy, multidisciplinary care, psychosocial impact

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review